Andrea Necchi, MD, discusses how results from the CA017-078 trials compares with other perioperative immunotherapy trials in muscle-invasive bladder cancer.
|Videos|July 18, 2021
Urologist Dr. Terrence Regan discusses prior authorization
Author(s)Urology Times staff
“[Prior authorization has] become part of our everyday practicing life, but it does very little to advance quality of care,” says Terrence Regan, MD.
Advertisement
In this video, Terrence Regan, MD, discusses his experience with obtaining prior authorizations. Regan is a urologist with Advanced Urology Institute in Palm Coast, Florida and serves as chair of the American Association of Clinical Urologists’ Health Policy Committee.
Advertisement
Related to this article
Daniel Heng, MD, discusses final LITESPARK-011 results, including sustained PFS benefit with belzutifan plus lenvatinib vs cabozantinib in advanced ccRCC.
Carlos A. Vargas, MD, discusses updated survival outcomes, safety, and the mechanism of SYNC-T SV-102, an investigational in situ immunotherapy for metastatic prostate cancer.
Kim Chi, MD, FRCPC, discusses the rationale and design of the phase 3 KLK2-comPAS trial evaluating pasritamig alone and in combination with JNJ-9401 in patients with mCRPC.
Engy Habashy, MD, discusses key takeaways from the 2025 AUA GSM guideline, including the role of androgens and hormonal therapies in managing genitourinary syndrome of menopause.
Michael S. Cookson, MD, MMHC, FACS, discusses how Anktiva’s expanded FDA approval may broaden bladder-preserving treatment options for BCG-unresponsive papillary-only NMIBC.
Jeffrey M. Spier, MD, reviews evidence on ARPI dose reduction in prostate cancer and discusses monitoring treatment response, tolerability, and dose reescalation.
Jeffrey M. Spier, MD, discusses managing ARPI-related fatigue through dose adjustments, patient monitoring, and strategies to maintain treatment adherence.
Advertisement
Advertisement
Trending on Urology Times
1
Adding darolutamide to ADT and radiation improves MFS in very high-risk localized prostate cancer
2
PROTEUS Substudy: Perioperative apalutamide plus ADT improves EFS vs surgery alone
3
Talazoparib/enzalutamide approved for HRR-mutated mAPMN/S prostate cancer
4
In situ immunotherapy shows encouraging survival findings in prostate cancer
5